ACTIV-1

Randomized Master Protocol for Immune Modulators for Treating COVID-1 (ACTIV-1 IM)

ACTIV-1 IM is a clinical trial designed to evaluate multiple immune modulators agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization.